Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 16, 2007 - Issue 7
Submit an article Journal homepage
264
Views
29
CrossRef citations to date
0
Altmetric
Review

Chronic obstructive pulmonary disease: role of matrix metalloproteases and future challenges of drug therapy

Punit K Srivastava, MD PhD Senior Research Scientist, Ranbaxy Research Laboratories, Department of Pharmacology, New Drug Discovery Research, Plot No-20, Sector-18, Udyog Vihar, Gurgaon, Haryana, 122001, India [email protected]
,
Sunanda G Dastidar Senior Research Scientist, Ranbaxy Research Laboratories, Department of Pharmacology, New Drug Discovery Research, Plot No-20, Sector-18, Udyog Vihar, Gurgaon, Haryana, 122001, India [email protected]
&
Abhijit Ray Senior Research Scientist, Ranbaxy Research Laboratories, Department of Pharmacology, New Drug Discovery Research, Plot No-20, Sector-18, Udyog Vihar, Gurgaon, Haryana, 122001, India [email protected]
Pages 1069-1078 | Published online: 26 Jun 2007

Bibliography

  • MATSUMOTO H, NIIMI A, TAKEMURA M et al.: Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibition in asthma. Thorax (2005) 60:277-281.
  • HOGG JC, CHU F, UTOKAPRACH S et al.: The nature of small-airway obstruction in chronic obstructive lung disease. N. Engl. J. Med. (2004) 350:2645-2654.
  • CELLI BR, MACNEE W: Standards for the diagnosis and treatment of patients with chronic obstructive pulmonary disease: a summary of the ATS/ERS position paper. Eur. Respir. J. (2004) 23:613-620.
  • PAUWELS RA, ROBE KI: Burden and clinical features of chronic obstructive pulmonary disease. Lancet (2004) 364:613-620.
  • FATMANN CL, CHANG LY, TERMIN TA et al.: Enhanced bleomycin induced pulmonary damage in mice lacking extra cellular superoxide dismutase. Br. J. Pharmacol. (2000) 131:169-172.
  • DAHESIA M: Therapeutic inhibition of matrix metalloproteinase for the treatment of chronic obstructive pulmonary disease (COPD). Curr. Med. Res. Opini. (2005) 21:557-593.
  • COSIO M, GHEZZO H, HOGG JC et al.: The relations between structural changes in small airway and pulmonary function tests. N. Engl. J. Med. (1978) 298:1277-1281.
  • PENMAN RW: The progress of chronic airway obstruction in relationship of asthma. Am. Rev. Respir. Dis. (1970) 101:536-544.
  • COLEBATCH HJ, FINUCARE KE, SMITH MM et al.: Pulmonary conductance and elastic recoil relationship in asthma and emphysema. J. Appl. Physiol. (1973) 34:143-153.
  • HOGG JC: Pathophysiology and airflow limitation in COPD. Lancet (2004) 364:709-721.
  • DI STEFANO A, CAPELLI A, FATTORETTI P et al.: Decreased T-lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin. Exp. Allergy (2001) 31:893-902.
  • DE BOER WI: Cytokines therapy in chronic obstructive pulmonary disease: a promising combination. Chest (2002) 121:2095-2185.
  • BARNES PJ, SHAPIRO SD, PAUWELS RA: Chronic obstructive pulmonary disease: molecular and cellular mechanism. Eur. Respir. J. (2003) 22:672-688.
  • GAULDIE J, KOLB M, SIME PJ: A new direction in the pathogenesis of idiopathic pulmonary fibrosis. Respir. Res. (2002) 3:1-12.
  • STRIEKER RM: Inflammatory mechanisms are not a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am. Respir. J. Crit. Care Med. (2002) 16:1206-1207.
  • SHAPIRO SD: COPD unwound. N. Engl. J. Med. (2005) 352:2016-2019.
  • LAGNTE V, MANOURY B, NENAN S et al.: Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Braz. J. Med. Biol. Res. (2005) 38:1521-1550.
  • SHAPIRO SD: Proteolysis in the lung. Eur. Respir. J. Suppl. (2003) 44: s30-s32.
  • BODE W, GOMIS-RUTH FX, STÖCKER W et al.: Astacins, serralysins, snake venom and MMP exhibit identical zinc binding environments (HEXXHXXGXXH & Met-turn) and topologist end should be grouped into common family, the metazincins. FEBS Lett. (2002) 331:134-140.
  • GOMIS-RUTH FX: Structural aspects of the metzincin class of metallopeptidase. Mol. Biotechnol. (2003) 24:157-202.
  • SATO H, TAKINO T, OKADA Y et al.: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature (1994) 370:61-65.
  • LOVEJOY B, CLEASTRY A, HASSEL AM et al.: Structure of the catalytic domain of fibroblast collagenase. Science (1994) 263:375-377.
  • STOCKET W, BODE W: Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr. Opin. Struct. Biol. (1995) 5:383-390.
  • NAGASE H, VISSE R, MURPHY G: Structure and function of matrix metalloproteinase and TIMPs. Cardiovas. Res. (2006) 69:562-573.
  • BABINE RE, BENDER SL: Molecular recognition of protein ligand complexes: application of drug design. Chem. Rev. (1997) 97:1359-1472.
  • WHITTAKER M, PLOYD CD, BROWN P et al.: Design and therapeutic application of MMP inhibitors. Chem. Rev. (1999) 99:2735-2776.
  • MARCHENKO MD, MARCHENKO GN, WEINBERG RN et al.: β-catenin regulates the gene of MMP-26, a novel metalloprotease expressed both in cancerous and normal epithelial cells. Int. J. Biochem. Cell Biol. (2004) 36:942-956.
  • MARTORMA PA, VAS EVEN P, GARDI C et al.: A 16 month study of the development of the genetic emphysema in the tight skin mice. Am. Rev. Respir. Dis. (1989) 139:226-232.
  • RANGA V, GRAHN D, JOURNEY TM: Macrophage and phenotypic analysis of outcross line of blotchy mouse. Am. Rev. Respir. Dis. (1983) 139:226-232.
  • WANDEL DP, TAYLOR DG, ALBERTINE KH et al.: Impaired distal airway development in mice lacking elastin. Respir. Cell Mol. Biol. (2000) 23:320-326.
  • HAUTAMAKI RD, KOBAYASHI DK, SENIOR RM et al.: Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science (1997) 277:2002-2004.
  • HOLEBECK K, BIANCO P, CATERINA J et al.: MT-1-MMP deficient mice develop dwarfism; osteropenia, arthritis and connective tissue disease due to inadequate collagen turn over. Cell (1999) 99:81-92.
  • SNIDER GL: Emphysema: the first centuries and beyond: a historical overview with suggestions for future research: part 2. Am. Rev. Respir. Dis. (1992) 146:1615-1622.
  • MASSARO GD, MASSARO D: Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat. Med. 3:675-677.
  • KUHN C, STARCHER BC: The effect of lathyrogens on the evolution of elastase-induced emphysema. Am. Rev. Respir. Dis. (1980) 122:453-460.
  • DE BOER WI: Perspectives for cytokine antagonist therapy in COPD. Drug Discov. Today (2005) 10:93-106.
  • RUSSELL RE, THORLEY A, CULPITT SV et al.: Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinase, cysteine and serine proteases. Am. J. Physiol. (2002) 283:L867-L873.
  • SUTHERLAND ER, CHERNIASK RM: Management of chronic obstructive pulmonary disease N. Engl. J. Med. (2004) 350:2689-2697.
  • OSHITA Y, KOGA T, KAMIMURA T et al.: Increased circulating 92 kDa matrix metalloproteinase (MMP-9) activity in exacerbations of asthma. Thorax (2003) 58:757-760.
  • MERCER PF, SHUTE JK, BHOWMIK A et al.: MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients drug exacerbation. Respir. Res. (2005) 22:151-159.
  • PETERSON JT: Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail. Rev. (2004) 91:63-79.
  • BIRRELL MA, SISSIE W, DEKKAK A et al.: Role of Matrix metalloproteases in the inflammatory response in human airway cell based assays and in rodent models of airway diseases. J. Pharmacol. Exp. Therap. (2006) 318:741-750.
  • LECLERC O, LAGENTE V, PLANQUOIS JM et al.: Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur. Respir. J. (2006) 27:1102-1109.
  • NOE V, FINGETON B, JACOBS K et al.: Release of an invasion promoter E-cadherin fragment by Matrilysin and Stromolysin-1. J. Cell Sci. (2001) 114:111-118.
  • STEINHUSEN U, WEIKE J, BADOK V et al.: Cleave and shedding of E-cadherin after induction of apoptosis. J. Biol. Chem. (2001) 276:4972-4980.
  • NING WN, YINYING D, SUN J et al.: Cigarette smoke stimulates matrix metalloproteinase-2 activity via EGR-1 in human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. (2007) 36:480-490.
  • MANNINO DM, GAGNON RC, PETTY TL, LYDICK E: Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey. Arch. Intern. Med. (2000) 160:1683-1689.
  • MANNINO DM, HOMA DM, AKINBAMI LJ, FORD ES, REDD SC: Chronic obstructive pulmonary disease surveillance–United States, 1971 – 2000. MMWR Surveill. Summ. (2002) 51:1-16.
  • FLETCHER C, PETO R, TINKER C et al.: The natural history of chronic bronchitis and emphysema. New York: Oxford University Press (1976).
  • O’DONNELL DE, LAM M, WEBB KA: Spirometric correlates of improvement in exercise performance after anti-cholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1999) 160:542-549.
  • RENNARD SI, SERBY CW, GHAFOURI M et al.: Extended therapy with ipatropium is associated with improved lung function in COPD: a retrospective analysis of data from seven clinical trials. Chest (1996) 110:62-70.
  • JARVIS B, MARKHAM A: Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging (2001) 18:441-472.
  • HANSEL TT, BARNES PJ: Tiotropium bromide: a novel once-daily anti-cholinergic bronchodilator for the treatment of COPD. Drugs Today (2002) 38:585-600.
  • BARNESS PJ: Theophylline: new perspective for an old drug. Am. J. Respir. Crit. Care Med. (2002) 165:1371-1376.
  • VESTBO J, SORENSEN T, LANGE P et al.: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet (1999) 353:1819-1823.
  • BURGE PS, CALVERLEY PM, JONES PW et al.: Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trail. BMJ (2000) 320:1297-1303.
  • CALVERLEY P, PAUWELS R, VESTBO J et al.: combined salmesterol and flucticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet (2003) 361:449-456.
  • BARNES PJ, HANSEL TT: Prospects for new drugs for chronic obstructive pulmonary disease. Lancet (2004) 364:985-996.
  • MACNEE W: Oxidants/antioxidants and COPD. Chest (2000) 117:S303-S317.
  • CULPITT SV, ROGERS DF, FENWICK PS et al.: Inhibition by red wine extract, resvertrol, of cytokine release by alveolar macrophages in COPD. Thorax (2003) 58:942-946.
  • MONTUSCHI P, KHARITONOV SA, CIABATTONI G et al.: Exhaled leukotrienes and prostaglandins in COPD. Thorax (2003) 58:585-988.
  • COMPTON CH, GUBB J, NEIMAN R et al.: Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomized, dose-ranging study. Lancet (2001) 358:265-270.
  • ROBICHAUD A, STAMATIOU PB, JIN SL et al.: Deletion of phosphodiesterase-4D in mice shortens α2-adrenoreceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. (2002) 110:1045-1052.
  • CHURG R, WANG R, WNG X et al.: An MMP-9/-12 inhibitor prevents smoke-induced emphysema and small airway remodeling in guinea pigs. Thorax (2007) 20: (In Press).
  • COUSSENS LM: Matrix metalloproteinase inhibitors and cancers: trials and tribulations. Science (2002) 295:2387-2392.
  • CUNIASSE P, DEVEL L, MAKARITIS A et al.: Future challenges facing the development of specific active-site directed synthetic inhibitors of MMPs. Biochimie (2005) 87:393-402.
  • LOPEZ-OTIN C, OVERALL CM: Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol. (2002) 3:509-519.
  • BERGERS G, BREKLEN R, MCMOHAN M et al.: MMP-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. (2000) 2:734-744.
  • ROSEMURGY A, HARRIS J, LANGLEBEN A et al.: Marimastat in patients with advanced pancreatic cancer: a dose finding study. Clin. Oncol. (1999) 99:2735-3776.
  • BROWN PD: Ongoing trials with MMP inhibitors. Expert Opin. Investig. Drugs (2000) 9:2167-2177.
  • WILSON S, WAKELAM MJO, HOBBS RFD et al.: Evaluation of the accuracy of serum MMP-9 as a test of colorectal cancer in a primary care population. Bio. Med. Central Cancer (2006) 6:258-264.
  • MOLFINO NA: Current thinking on genetics of chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. (2006) 13:107-113.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.